MedTrace Logo

Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia

NCT07760961 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-08-12

No results posted yet for this study

Summary

VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.

Conditions

Interventions

DRUG

Mizagliflozin 5 mg

5mg mizagliflozin capsules orally administered TID for 28 days

DRUG

Mizagliflozin 10 mg

10mg mizagliflozin capsules orally administered TID for 28 days

DRUG

Placebo

Placebo capsules orally administered TID for 28 days

Sponsors & Collaborators

  • Vogenx, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2027-10-31
Completion
2028-01-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07760961 on ClinicalTrials.gov